| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1384SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-139SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-616SS | |||
| Azide and BSA Free | NBP2-80820 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77456SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 405 | NBP2-12878AF405 | |||
| Alexa Fluor 488 | NBP2-12878AF488 | |||
| Alexa Fluor 647 | NBP2-12878AF647 | |||
| Alexa Fluor 700 | NBP2-12878AF700 | |||
| DyLight 350 | NBP2-12878UV | |||
| DyLight 405 | NBP2-12878V | |||
| DyLight 488 | NBP2-12878G | |||
| DyLight 680 | NBP2-12878FR | |||
| DyLight 755 | NBP2-12878IR | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1384SS | |||
| BSA Free | NB600-1384 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-139SS | |||
| BSA Free | NB100-139 | |||
![Analysis of LC3B in HeLa cells using anti-LC3B antibody (red) [Catalog # NB600-1384]. Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/LC3B-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1384-img0033.jpg)
![Analysis of LC3B in treated U87-MG (human glioblastoma astrocytoma) lysates using anti- [Catalog # NB600-1384].](http://images.novusbio.com/fullsize/LC3B-Antibody---BSA-Free-Western-Blot-NB600-1384-img0027.jpg)
![Staining of treated U373-MG (human glioblastoma) cells using anti- [Catalog # NB600-1384].](http://images.novusbio.com/fullsize/LC3B-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1384-img0030.jpg)
![Analysis of U87MG glioma xenografts using anti- [Catalog # NB600-1384]. Image from verified customer review.](http://images.novusbio.com/fullsize/LC3B-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NB600-1384-img0023.jpg)
![G-TPP induces PINK1 stabilization and kinase activity in HeLa cells(A) G-TPP treatment leads to PINK1 stabilization and pS65-Ub induction in HeLa cells. HeLa cells stably expressing untagged Parkin were treated with 10 µM G-TPP for the indicated times. Western blots were prepared with cell lysates and probed with antibodies against PINK1 and pS65-Ub. GAPDH served as a loading control. (B) pS65-Ub is induced in G-TPP treated cells and co-localizes with EGFP-Parkin and mitochondria. HeLa cells stably expressing EGFP-Parkin (green) were treated with 10 µM G-TPP for the indicated times and fixed. Cells were stained with antibodies against pS65-Ub (red) and the mitochondrial marker TOM20 (cyan). Scale bars correspond to 10 µM. (C) Quantification of Parkin translocation using High Content Imaging. HeLa EGFP-Parkin cells were treated for 4 or 8 h with or without 10 µM G-TPP. CCCP treatment (10 µM for 2 h) was used as a positive control. Cells were fixed, counterstained with Hoechst dye to visualize nuclei, imaged and analyzed using the ratio of cytoplasmic to nuclear EGFP signal [21]. Data was normalized to positive (2 h 10 µM CCCP treatment) and negative (2 h DMSO) controls. G-TPP significantly induced Parkin re-localization to levels similar to or beyond 2 h CCCP treatment. Shown are the mean values of three independent experiments with triplicate wells each ± SEM (one-way ANOVA with Tukey’s posthoc, ***p < 0.0005). Image collected and cropped by CiteAb from the following open publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22287), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-2322024894222.jpg)
![Knockdown Validated: EGLN3/PHD3 Antibody [NB100-139] - PHD3 is required for SCC cell survival in prolonged hypoxia. PHD3 is induced in hypoxia. Knock-down of PHD3 expression with siRNA (siPHD3) is specific and does not affect PHD2 or HIF-1 alpha expression. siScr = scrambled control siRNA. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0014617), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN3-PHD3-Antibody-Knockdown-Validated-NB100-139-img0017.jpg "<b>Genetic Strategies Validation. </b>Knockdown Validated: EGLN3/PHD3 Antibody [NB100-139] - PHD3 is required for SCC cell survival in prolonged hypoxia. PHD3 is induced in hypoxia. Knock-down of PHD3 expression with siRNA (siPHD3) is specific and does not affect PHD2 or HIF-1 alpha expression. siScr = scrambled control siRNA. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0014617), licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry-Paraffin: EGLN3/PHD3 Antibody [NB100-139] - Analysis of a formalin fixed tissue section of human renal cell carcinoma (clear cell type) using rabbit polyclonal EGLN3/PHD3 antibody with HRP-DAB detection and hematoxylin counterstaining. The antibody generated a strong nuclear staining of PHD3 primarily in the cancer cells while the stromal cells were largely negative for this protein.](http://images.novusbio.com/fullsize/EGLN3-PHD3-Antibody-Immunohistochemistry-Paraffin-NB100-139-img0010.jpg)
![<b>Genetic Strategies Validation. </b>Knockdown Validated: EGLN3/PHD3 Antibody [NB100-139] - EGLN3/PHD3 depletion increases S10 phosphorylation of p27 in hypoxia. S10 phosphorylated form of p27 is strongly induced in EGLN3/PHD3 depleted cells. Image collected and cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0410-5) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN3-PHD3-Antibody-Knockdown-Validated-NB100-139-img0019.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN3/PHD3 Antibody [NB100-139] - EGLN3/PHD3 antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/EGLN3-PHD3-Antibody-Immunocytochemistry-Immunofluorescence-NB100-139-img0014.jpg)
![<b>Genetic Strategies Validation. </b>Knockdown Validated: EGLN3/PHD3 Antibody [NB100-139] - BxPC3 cells stably transduced with retrovirus containing PHD3Wt (BxPC3-Wt), Vector (BxPC3-Vec) or anti-PHD3 shRNA (BxPC3-KD) were harvested for RNA and protein following 24 hours exposure to normoxia (21% O2) or hypoxia (1% O2). Whole cell lysate from BxPC3-Wt, BxPC3-Vec and BxPC3-KD cells following 24 hours exposure to normoxia (N) or hypoxia (H) was resolved by SDS-PAGE and blotted for actin (top) and PHD3 (bottom). PHD3 band intensity was quantified relative to actin in each lane and then normalized to BxPC3-Vec (N). Relative band intensity is indicated below the figure. NS = non-specific band running just above PHD3 band. Data is representative of >3 biological replicates. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0083021), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN3-PHD3-Antibody-Knockdown-Validated-NB100-139-img0016.jpg)
![Western Blot: EGLN3/PHD3 Antibody [NB100-139] - The HIF-1 response is not impaired in prostate and breast carcinoma cell lines that lack PHD3. Melanoma, breast and prostate cancer cell lines with methylated PHD3 promoters (MB-435, PC-3) and non-methylated promoters (MCF7, DU 145) were subjected to hypoxia (1% O2) or normoxia for 24 hours. Thirty micrograms of whole cell lysate was western blotted for the presence of PHD3; actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0014617), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN3-PHD3-Antibody-Western-Blot-NB100-139-img0018.jpg)
![Western Blot: EGLN3/PHD3 Antibody [NB100-139] - Analysis of HeLa lysates using NB100-139. Image courtesy of Dr Gregg Semenza (The Johns Hopkins University School of Medicine, Baltimore, MD USA)](http://images.novusbio.com/fullsize/EGLN3-PHD3-Antibody-Western-Blot-NB100-139-img0013.jpg)
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Analysis of astrocytes lysate from Rat brain using FIH-1/HIF-1AN antibody at 1:500 dilution with ECL detection. The antibody detected a major band at ~40 kDa position representing FIH-1/HIF-1AN protein.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0007.jpg "Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Analysis of astrocytes lysate from Rat brain using FIH-1/HIF-1AN antibody at 1:500 dilution with ECL detection. The antibody detected a major band at ~40 kDa position representing FIH-1/HIF-1AN protein.")
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Representative picture of western blot in histopathologically unchanged tissue (N) and primary cancerous tissue (C) from patients with CRC. Immunodetection of bands was performed with Rp anti- PHD1 (Catalog # NB100-310), - PHD2 (Catalog # NB100-137), - PHD3 (Catalog # NB100-139) and -FIH-1/HIF-1AN Ab (Catalog # NB100-139), followed by incubation with goat anti-rabbit HRP-conjugated Ab. The membrane was stripped and incubated with Rp anti-GAPDH Ab, followed by incubation with goat anti-rabbit HRP-conjugated Ab. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-526), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0010.jpg)
![Immunohistochemistry: FIH-1/HIF-1AN Antibody [NB100-428] - Detection of FIH-1 in rat brain tissue.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Immunohistochemistry-NB100-428-img0008.jpg)
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Rat VSMC (vascular smoot muscle) cells treated (siFIH) or not (CTL) with a specific siRNA against FIH-1. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0009.jpg)
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Knockdown Validated: FIH-1/HIF-1AN Antibody [NB100-428] - (C) Cytoplasmic FIH-1 (lower band) and MMP14 expression levels in both aerobic and hypoxic conditions in the 3 cell lines. (E) siRNA targeting FIH-1 was used to assess whether FIH-1 had any effect on CAIX expression in MCF-7 cells cultured in 0.5% O2 conditions. cont, control. m, transfection reagent alone. scr, scrambled siRNA. pool, mixture of 4 siRNAs targeting FIH-1. 21, single siRNA targeting FIH-1. (F) FIH-1 and CAIX expression levels in aerobic MCF-7 cells treated with either siRNA against FIH-1 alone, or both 400 uM CoCl2 and siRNA together for 24, 48 and 72h. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28476026/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN Antibody-Knockdown Validated-NB100-428-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW105) [NB100-616] - HeLa cells were fixed in 4% paraformaldehyde for 10 min and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B Antibody (RW105)) at 5ug/ml for 60 minutes at room temperature and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Immunocytochemistry-Immunofluorescence-NB100-616-img0005.jpg "Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW105) [NB100-616] - HeLa cells were fixed in 4% paraformaldehyde for 10 min and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B Antibody (RW105)) at 5ug/ml for 60 minutes at room temperature and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective.")
![Western Blot: KAT3B/p300 Antibody (RW105) [NB100-616] - p300 detected in a HeLa nuclear extract using NB 100-616 (1:250). ECL: 20 minute exposure.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Western-Blot-NB100-616-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW105) [NB100-616] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B/p300 Antibody (RW105) NB100-616 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Immunocytochemistry-Immunofluorescence-NB100-616-img0008.jpg)
![Flow Cytometry: KAT3B/p300 Antibody (RW105) [NB100-616] - An intracellular stain was performed on RAW 246.7 cells with KAT3B/p300 antibody (RW105) NB100-616PE (blue) and a matched isotype control NBP2-27287PE (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin. Image using the PE format of this antibody.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Flow-Cytometry-NB100-616-img0006.jpg)
![Flow (Intracellular): KAT3B/p300 Antibody (RW105) [NB100-616] - An intracellular stain was performed on THP-1 cells with KAT3B/p300 (RW105) antibody NB100-616 (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and permeabilized with 0.1% Saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Flow-Intracellular-NB100-616-img0003.jpg)
![Flow Cytometry: KAT3B/p300 Antibody (RW105) [NB100-616] - An intracellular stain was performed on Raw264.7 cells with KAT3B/p300 Antibody (RW105) NB100-616 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Flow-Cytometry-NB100-616-img0007.jpg)
![<b>Genetic Strategies Validation. </b>Knockdown Validated: KAT3B/p300 Antibody (RW105) [NB100-616] - 293T cells were treated with different siRNAs against p300 alone for 2 days and core histones were prepared and subjected to WB analysis as indicated. The knockdown efficiency of p300 was confirmed by WB analysis of cell lysates. Western Blot protocol is 6% gel for running, 40V overnight transfer membrane. primary Ab 1:500, secondary Ab 1:5000. Image from verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-616_mouse-monoclonal-kat3b-p300-antibody-rw105-knockdown-validated-147202311647.jpg)
![Western Blot: HSP70/HSPA1A Antibody [NBP1-77456] - Analysis of HSP70 in (1) human brain, (2) human liver, (3) human testes, (4) human skeletal muscle, and (5) human heart.](http://images.novusbio.com/fullsize/HSP70-HSPA1A-Antibody-Western-Blot-NBP1-77456-img0004.jpg "Western Blot: HSP70/HSPA1A Antibody [NBP1-77456] - Analysis of HSP70 in (1) human brain, (2) human liver, (3) human testes, (4) human skeletal muscle, and (5) human heart.")
![Immunohistochemistry: HSP70/HSPA1A Antibody [NBP1-77456] - Analysis of Hsp70 in human xenograft kidney cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/HSP70-HSPA1A-Antibody-Immunohistochemistry-NBP1-77456-img0003.jpg)
![Simple Western: HSP70/HSPA1A Antibody [NBP1-77456] - Lane view shows a specific band for Hsp70 in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230kDa separation system.](http://images.novusbio.com/fullsize/HSP70-HSPA1A-Antibody-Simple-Western-NBP1-77456-img0005.jpg)
![Western Blot: HSP90 Antibody (4F3.E8) [NBP2-12878] - Western Blot analysis of Rat tissue lysate showing detection of Hsp90 protein using Mouse Anti-Hsp90 Monoclonal Antibody, Clone 4F3.E8 (NBP2-12878). Load: 15 ug. Block: 1.5% BSA for 30 minutes at RT. Primary Antibody: Mouse Anti-Hsp90 Monoclonal Antibody (NBP2-12878) at 1:1000 for 2 hours at RT. Secondary Antibody: Sheep Anti-Mouse IgG: HRP for 1 hour at RT.](http://images.novusbio.com/fullsize/HSP90-Antibody-4F3-E8-Western-Blot-NBP2-12878-img0011.jpg "Western Blot: HSP90 Antibody (4F3.E8) [NBP2-12878] - Western Blot analysis of Rat tissue lysate showing detection of Hsp90 protein using Mouse Anti-Hsp90 Monoclonal Antibody, Clone 4F3.E8 (NBP2-12878). Load: 15 ug. Block: 1.5% BSA for 30 minutes at RT. Primary Antibody: Mouse Anti-Hsp90 Monoclonal Antibody (NBP2-12878) at 1:1000 for 2 hours at RT. Secondary Antibody: Sheep Anti-Mouse IgG: HRP for 1 hour at RT.")
![Immunocytochemistry/Immunofluorescence: HSP90 Antibody (4F3.E8) [NBP2-12878] - Tissue: HaCaT cells. Species: Human. Fixation: Cold 100% methanol for 10 minutes at -20C. Primary Antibody: Mouse Anti-Hsp90 Monoclonal Antibody at 1:100 for 1 hour at RT. Secondary Antibody: FITC Goat Anti-Mouse (green) at 1:50 for 1 hour at RT.](http://images.novusbio.com/fullsize/HSP90-Antibody-4F3-E8-Immunocytochemistry-Immunofluorescence-NBP2-12878-img0007.jpg)
![Immunohistochemistry: HSP90 Antibody (4F3.E8) [NBP2-12878] - Immunohistochemistry analysis using Mouse Anti-Hsp90 Monoclonal Antibody, Clone 4F3.E8 (NBP2-12878). Tissue: backskin. Species: Mouse. Fixation: Bouin's Fixative and paraffin-embedded. Primary Antibody: Mouse Anti-Hsp90 Monoclonal Antibody (NBP2-12878) at 1:100 for 1 hour at RT. Secondary Antibody: FITC Goat Anti-Mouse (green) at 1:50 for 1 hour at RT.](http://images.novusbio.com/fullsize/HSP90-Antibody-4F3-E8-Immunohistochemistry-NBP2-12878-img0014.jpg)
![Immunohistochemistry: HSP90 Antibody (4F3.E8) [NBP2-12878] - Immunohistochemistry analysis using Mouse Anti-Hsp90 Monoclonal Antibody, Clone 4F3.E8 (NBP2-12878). Tissue: colon carcinoma. Species: Human. Fixation: Formalin. Primary Antibody: Mouse Anti-Hsp90 Monoclonal Antibody (NBP2-12878) at 1:100000 for 12 hours at 4C. Secondary Antibody: Biotin Goat Anti-Mouse at 1:2000 for 1 hour at RT. Counterstain: Mayer Hematoxylin (purple/blue) nuclear stain at 200 l for 2 minutes at RT. Localization: Inflammatory cells. Magnification: 40x.](http://images.novusbio.com/fullsize/HSP90-Antibody-4F3-E8-Immunohistochemistry-NBP2-12878-img0012.jpg)
![Immunohistochemistry: HSP90 Antibody (4F3.E8) [NBP2-12878] - Immunohistochemistry analysis using Mouse Anti-Hsp90 Monoclonal Antibody, Clone 4F3.E8 (NBP2-12878). Tissue: muscle tissue. Species: Mouse. Fixation: Bouin's Fixative and paraffin-embedded. Primary Antibody: Mouse Anti-Hsp90 Monoclonal Antibody (NBP2-12878) at 1:1000 for 1 hour at RT. Secondary Antibody: FITC Goat Anti-Mouse (green) at 1:50 for 1 hour at RT.](http://images.novusbio.com/fullsize/HSP90-Antibody-4F3-E8-Immunohistochemistry-NBP2-12878-img0013.jpg)
![Western Blot: HSP70/HSPA1A Antibody (N27F3-4) [NB110-96425] - analysis of Human Cell lysates showing detection of Hsp70 protein using Mouse Anti-Hsp70 Monoclonal Antibody, Clone N27 . Load: 15 ug protein. Block: 1.5% BSA for 30 minutes at RT. Primary Antibody: Mouse Anti-Hsp70 Monoclonal Antibody at 1:1000 for 2 hours at RT. Secondary Antibody: Sheep Anti-Mouse IgG: HRP for 1 hour at RT.](http://images.novusbio.com/fullsize/HSP70-HSPA1A-Antibody-N27F3-4-Western-Blot-NB110-96425-img0004.jpg "Western Blot: HSP70/HSPA1A Antibody (N27F3-4) [NB110-96425] - analysis of Human Cell lysates showing detection of Hsp70 protein using Mouse Anti-Hsp70 Monoclonal Antibody, Clone N27 . Load: 15 ug protein. Block: 1.5% BSA for 30 minutes at RT. Primary Antibody: Mouse Anti-Hsp70 Monoclonal Antibody at 1:1000 for 2 hours at RT. Secondary Antibody: Sheep Anti-Mouse IgG: HRP for 1 hour at RT.")
![Immunohistochemistry: HSP70/HSPA1A Antibody (N27F3-4) [NB110-96425] - Immunohistochemistry analysis using Mouse Anti-Hsp70 Monoclonal Antibody, Clone N27F3-4 (NB110-96425). Tissue: backskin. Species: Mouse. Fixation: Bouin's Fixative and paraffin-embedded. Primary Antibody: Mouse Anti-Hsp70 Monoclonal Antibody (NB110-96425) at 1:100 for 1 hour at RT. Secondary Antibody: FITC Goat Anti-Mouse (green) at 1:50 for 1 hour at RT. Localization: Epidermis.](http://images.novusbio.com/fullsize/HSP70-HSPA1A-Antibody-N27F3-4-Immunohistochemistry-NB110-96425-img0007.jpg)
![Western Blot: PHD4/HIF Prolyl Hydroxylase 4 Antibody [NB100-295] - Samples: Whole cell lysate (50 ug) from HeLa and 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-PHD4 antibody used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/PHD4-HIF-Prolyl-Hydroxylase-4-Antibody-Western-Blot-NB100-295-img0007.jpg "Western Blot: PHD4/HIF Prolyl Hydroxylase 4 Antibody [NB100-295] - Samples: Whole cell lysate (50 ug) from HeLa and 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-PHD4 antibody used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Western Blot: PHD4/HIF Prolyl Hydroxylase 4 Antibody [NB100-295] - Analysis of human PHD4, using NB100-295. Samples: whole cell lysate from HeLa cells, normoxic and hypoxic, respectively.](http://images.novusbio.com/fullsize/PHD4-HIF-Prolyl-Hydroxylase-4-Antibody-Western-Blot-NB100-295-img0004.jpg)
![Western Blot: PHD4/HIF Prolyl Hydroxylase 4 Antibody [NB100-295] - Whole cell lysate (25 mcg/lane) from human glioblastoma tumor cell lines or in vitro translated PHD4. Antibody: Affinity purified rabbit anti-PHD4 (Cat. No. NB100-295) used at 2 mcg/ml. Detection: Chemiluminescence](http://images.novusbio.com/fullsize/PHD4-HIF-Prolyl-Hydroxylase-4-Antibody-Western-Blot-NB100-295-img0006.jpg)